Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602367 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01602367 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 7 participants.
The verdict
NCT01602367, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-823778 is safe and effective in the treatment of hypertension in overweight and obese patients.
Interventions
- DRUG BMS-823778
- DRUG Placebo matching with BMS-823778
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01602367
The ClinicalTrials.gov registry entry for NCT01602367 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-823778 is the first listed.
NCT01602367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01602367 about?
NCT01602367 is a clinical study titled "Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients". The purpose of this study is to determine whether BMS-823778 is safe and effective in the treatment of hypertension in overweight and obese patients.
What is the current status of trial NCT01602367?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2012-07. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01602367?
The interventions under investigation include: BMS-823778 (DRUG), Placebo matching with BMS-823778 (DRUG).
Who is sponsoring clinical trial NCT01602367?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.